Affiliation:
1. Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India
Abstract
In order for clinical practise, public health efforts, and effective drug regulatory systems to function effectively, pharmacovigilance—the term used to describe the processes for recording and analysing adverse drug reactions—must be implemented. A high level of skill is required to grasp pharmacovigilance in order to swiftly identify pharmacological dangers and to defend the product against an unjustified withdrawal. The volume of data handled has increased as a result of the reporting of number of the adverse drug reactions (ADRs). The present global network of pharmacovigilance centres, which is supervised by the Uppsala Monitoring Center, would be strengthened by an independent review procedure. This would consider disputed and important pharmaceutical safety problems that might have a detrimental effect on public health across international borders. Recently, the main goal of pharmacovigilance has been to identify previously unrecognised or poorly understood adverse drug reactions. Clinical research must include pharmacovigilance, which is becoming more and more popular in many countries. To improve drug safety and monitoring, pharmacovigilance faces significant obstacles at the turn of the millennium. Currently, a number of pharmacovigilance centres are engaged in this global effort to monitor the safety of pharmaceuticals. We'll discuss medication safety, the role of worldwide pharmacovigilance centres, the benefits and downsides of pharmacovigilance, and how the healthcare sector can employ it in the future in this review. (4) Pharmacovigilance encourages the correct and safe use of drugs. Adverse drug responses (ADRs) must be reported spontaneously, and this is a crucial part of pharmacovigilance. ADRs are, nonetheless, considerably underreported. In developing nations, adverse medication responses are now a significant issue. Understanding pharmacovigilance could serve as the foundation for actions meant to increase reporting rates and lower ADRs. (1).
Reference16 articles.
1. Ankur Rohilla, Nishant Singh, Vipin Kumar, Amarjeet Dahiya, Review article of the Pharmacovigilance.
2. Dr. Satish Sharma. Method of Pharmacovigilance.
3. Pharmacovigilance Programme of India Duvvuru Ashok Kumar*, Languluri Reddenna, Shaik Ayub Basha.
4. Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring. G.Jeetu and G.Anusha.
5. Olsson S. Pharmacovigilance training with focus on India. Ind J Pharmacol 2008:40:S28-S30.